202 related articles for article (PubMed ID: 32598795)
21. Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis.
Nguyen TQ; Hanh BTB; Jeon S; Heo BE; Park Y; Choudhary A; Moon C; Jang J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0044822. PubMed ID: 36321819
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives.
Peng CT; Gao C; Wang NY; You XY; Zhang LD; Zhu YX; Xv Y; Zuo WQ; Ran K; Deng HX; Lei Q; Xiao KJ; Yu LT
Bioorg Med Chem Lett; 2015 Apr; 25(7):1373-6. PubMed ID: 25754492
[TBL] [Abstract][Full Text] [Related]
23. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
24. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.
Li P; Wang B; Zhang X; Batt SM; Besra GS; Zhang T; Ma C; Zhang D; Lin Z; Li G; Huang H; Lu Y
Eur J Med Chem; 2018 Dec; 160():157-170. PubMed ID: 30336450
[TBL] [Abstract][Full Text] [Related]
26. Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs.
Koryakova A; Shcherbakova V; Riabova O; Kazaishvili Y; Bolgarin R; Makarov V
Microbiol Spectr; 2023 Feb; 11(1):e0232722. PubMed ID: 36507624
[TBL] [Abstract][Full Text] [Related]
27. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
[TBL] [Abstract][Full Text] [Related]
29. DprE1--from the discovery to the promising tuberculosis drug target.
Mikusová K; Makarov V; Neres J
Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
[TBL] [Abstract][Full Text] [Related]
30. Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.
Wang A; Ma C; Chai Y; Liu X; Lv K; Fu L; Wang B; Jia X; Liu M; Lu Y
Eur J Med Chem; 2020 Aug; 200():112409. PubMed ID: 32460114
[TBL] [Abstract][Full Text] [Related]
31. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
32. Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis.
Lechartier B; Cole ST
Antimicrob Agents Chemother; 2015 Aug; 59(8):4457-63. PubMed ID: 25987624
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals.
Xiong L; Gao C; Shi YJ; Tao X; Peng CT; Rong J; Liu KL; Lei Q; Zhang YW; Wang NY; Yu LT
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686156
[TBL] [Abstract][Full Text] [Related]
34. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
35. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
[TBL] [Abstract][Full Text] [Related]
36. Quinolone analogues of benzothiazinone: Synthesis, antitubercular structure-activity relationship and ADME profiling.
Dube PS; Legoabe LJ; Jordaan A; Sigauke L; Warner DF; Beteck RM
Eur J Med Chem; 2023 Oct; 258():115539. PubMed ID: 37321107
[TBL] [Abstract][Full Text] [Related]
37. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
38. Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis.
Chen X; Li Y; Wang B; Lu Y
Curr Microbiol; 2022 May; 79(7):205. PubMed ID: 35616769
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of macozinone in mice with genetically diverse susceptibility to Mycobacterium tuberculosis infection.
Nikonenko B; Logunova N; Egorova A; Kapina M; Sterzhanova N; Bocharova I; Kondratieva E; Riabova O; Semyonova L; Makarov V;
Microbes Infect; 2024 Jun; ():105376. PubMed ID: 38852904
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, structures, reactivity and medicinal chemistry of antitubercular benzothiazinones.
Seidel RW; Richter A; Goddard R; Imming P
Chem Commun (Camb); 2023 Apr; 59(32):4697-4715. PubMed ID: 36974371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
